Name: Mineralys Therapeutics, Inc. (MLYS) Cash Flow Statement
Creator: FinSpry

Mineralys Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Mineralys Therapeutics, Inc. (MLYS) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Operating Activities
Net Income	-177.81	-71.90	-29.80	-19.41	-3.43
Depreciation & Amortization	0.04	0.00	0.00	0.00	0.00
Stock Based Compensation	11.34	5.06	0.46	0.08	0.00
Change in Working Capital	9.52	-7.47	0.77	4.09	0.48
Change in Accounts Receivable	0.42	0.00	0.00	0.00	0.00
Change in Accounts Payable	4.16	2.42	3.01	4.47	0.54
Change in Other Working Capital	5.36	-9.89	-0.65	0.68	-0.06
Other Operating Activities	-9.41	-1.81	-0.65	0.68	0.48
Net Cash from Operating Activities	-166.31	-81.17	-29.22	-14.56	-2.46
Investing Activities
Capital Expenditures	-0.10	0.00	0.00	0.00	0.00
Purchases of Investments	115.06	-160.47	-71.76	0.00	0.00
Sales/Maturities of Investments	488.50	187.50	50.00	0.00	0.00
Net Cash from Investing Activities	114.96	-160.47	-21.76	0.00	0.00
Financing Activities
Common Stock Issued	116.58	203.25	129.65	0.00	0.00
Common Stock Repurchased	0.00	0.00	-1.63	0.00	0.00
Other Financing Activities	-0.44	0.00	-1.63	0.00	-0.02
Net Cash from Financing Activities	116.14	203.25	128.02	23.81	3.83
Summary
Net Change in Cash	64.79	-38.40	77.04	9.25	1.37
Cash at Beginning of Period	49.30	87.70	10.66	1.41	0.00
Cash at End of Period	114.09	-81.17	87.70	10.66	0.00
Free Cash Flow	-166.41	-81.17	-29.22	-14.56	-2.46